A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Exclusion Criteria

• •Has a history of type 1 diabetes mellitus or a history of ketoacidosis
• •Has a history of secondary causes of diabetes
• •Has a known hypersensitivity or intolerance to any dipeptidyl peptidase IV (DPP-4) inhibitor or sodium-glucose cotransporter 2 (SGLT2) inhibitor
• •Has been treated with any anti-hyperglycemic agents (AHA) other than metformin and for participants on dual combination therapy, a sulfonylurea within 12 weeks of screening
• •Intends to initiate weight loss medication during the study period
• •Has undergone bariatric surgery within 12 months of Screening visit
• •Has started a weight loss medication or a medication associated with weight changes within the prior 12 weeks.
• •Has a history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, heart failure within 3 months of Screening visit
• •Has a history of malignancy ≤5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
• •Has human immunodeficiency virus (HIV)
• •Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
• •Has a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
• •Is currently being treated for hyperthyroidism or is on thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to Screening visit
• •Is on or likely to require treatment for ≥14 consecutive days or repeated courses of corticosteroids
• •Is on or likely to require treatment for ≥7 consecutive days with non-steroidal anti-inflammatory drugs
• •Is pregnant or breast-feeding, or is planning to conceive during the study, including 14 days following the last dose of blinded study drug
• •Is planning to undergo hormonal therapy in preparation to donate eggs during the study, including 14 days following the last dose of blinded study drug
• •Routinely consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week or engages in binge drinking
• •Has donated blood or blood products within 6 weeks of Screening visit or who plans to donate blood or blood products at any time during the study